Health Care Equipment

PAVmed

PAVmed Reports Q3 Earnings Below Expectations

PAVmed released FY2025 9 Months Earnings on November 12 Pre-Market (EST), actual revenue USD 19K, actual EPS USD -0.6935

PAVmed released FY2025 Q3 earnings on November 12 Pre-Market EST, actual revenue USD 5 K (forecast USD 12.5 K), actual EPS USD -0.2935 (forecast USD -0.17)

PAVmed to Release FY2025 Q3 Earnings on November 13, Pre-Market EST; Forecast Revenue USD 12.5 K, EPS USD -0.17

PAVmed released FY2025 Q2 earnings on August 14 Pre-Market (EST), actual revenue USD 6K (forecast USD 10K), actual EPS USD -0.7399 (forecast USD -0.13)

PAVmed released FY2025 Semi-Annual earnings on August 14 Pre-Market EST, actual revenue USD 14 K, actual EPS USD 0.1299

PAVmed to Release FY2025 Q2 Earnings on August 13 Pre-Market (EST), Forecast Revenue USD 10K, EPS USD -0.13

Veris Health Inc. Secures $2.5M in Private Equity Funding for Physiological Monitor Development

Ascendiant Capital Maintains Buy Rating on PAVmed and Adjusts Price Target

PAVmed released FY2025 Q1 earnings on May 15 Pre-Market EST, actual revenue USD 8K (forecast USD 10K), actual EPS USD 0.3399 (forecast USD 0.29)

PAVmed to Report Q1 2025 Earnings

PAVmed Inc projects Q1 EPS loss of 13 cents and significant revenue decline

PAVmed to release FY2025 Q1 earnings report on May 15 Pre-Market EST, forecast revenue USD 10 K, EPS USD 0.29

PAVmed Inc. releases Q1 2025 financial results

Ascendiant Capital Maintains PAVmed Rating and Raises Price Target

PAVmed Q4 2024 Earnings Call Highlights Contradictions in FDA Timeline and Funding

PAVmed Inc Reports Significant Improvement in Quarterly Adjusted Earnings

PAVmed released FY2024 Q4 earnings on March 24 Pre-Market (EST), actual revenue 10 K USD (forecast 580 K USD), actual EPS -0.0121 USD (forecast -0.11 USD)

PAVmed released FY2024 annual earnings on March 24 Pre-Market (EST), actual revenue 2.995 M USD (forecast 3.013 M USD), actual EPS 0.4961 USD (forecast 2.5 USD)

PAVmed to Release FY2024 Q4 Earnings on March 25, 2025, Pre-Market EST; Forecast Revenue 580K USD, EPS -0.11 USD

SEVEN HILLS RLTY TR COM USD0.001 (S/R 04/12/2025)

SMX Security Matters

Polyrizon

Picard Medical

Synchronoss Tech

PharmaCyte Biotech

Q/C Tech

Rich Sparkle

Hoyne Bancorp

Tradr 2X Long ASTS Daily ETF

Delcath

Electromed

Abbott Laboratories

Intuitive Surgical

Boston Scientific

Stryker

IDEXX Labs

Edwards Lifesciences

Resmed

Steris

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap